32 terminated. 32 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 32 | Terminated 32 |
| Phase 2 | 6 | Terminated 6 |
Follow Stomach Diseases: new trials by email Literature Review of Stomach Diseases trials Research Report on Stomach Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. Bemarituzumab, Nivolumab, Chemotherapy - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Terminated | Amgen | 515 | 2022-03-14 | 2026-09-10 |
| Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) Benralizumab, Placebo - Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 3 | Terminated | AstraZeneca | 12 | 2022-01-18 | 2025-07-14 |
| Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer Preoperative Chemotherapy, Surgery, Postoperative chemotherapy - Gastric Adenocarcinoma | Phase 3 | Terminated | University Hospital, Lille | 6 | 2021-08-25 | 2025-12-23 |
| Diabetic Gastroparesis Study 05 Relamorelin 10 μg - Gastroparesis | Phase 3 | Terminated | Allergan | 202 | 2018-12-20 | 2021-12-15 |
| Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02 Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus | Phase 3 | Terminated | Allergan | 311 | 2018-02-16 | 2021-08-06 |
| A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04 Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus | Phase 3 | Terminated | Allergan | 450 | 2018-02-01 | 2021-11-23 |
| A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus | Phase 3 | Terminated | Allergan | 467 | 2018-01-24 | 2021-12-22 |
| A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus | Phase 3 | Terminated | Allergan | 336 | 2017-09-29 | 2021-07-29 |
| Efficacy and Safety of DWC20155/DWC20156 Combination Therapy in Patients With Gastritis DWC20155, DWC20156, placebo of DWC20155 - Gastritis | Phase 3 | Terminated | Daewoong Pharmaceutical Co. LTD. | 230 | 2017-07-03 | 2019-06-26 |
| Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer Oxaliplatin plus S-1, S-1 only - Gastric Cancer | Phase 3 | Terminated | Peking University Cancer Hospital & Institute | 29 | 2017-04-24 | 2024-12-03 |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) Pembrolizumab, Paclitaxel - Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 94 | 2017-02-16 | 2023-03-30 |
| Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis Proton-pump inhibitor, Propranolol+Proton-pump inhibitor - Liver Cirrhosis, Peptic Ulcer | Phase 2 / Phase 3 | Terminated | Taipei Veterans General Hospital, Taiwan | 10 | 2016-12-26 | 2020-06-23 |
| A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer Rilotumumab, Placebo, Cisplatin - Gastric Cancer | Phase 3 | Terminated | Amgen | 34 | 2014-07-01 | 2016-04-04 |
| Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer Irinotecan, Nimotuzumab - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Terminated | Kuhnil Pharmaceutical Co., Ltd. | 400 | 2013-05-13 | 2018-03-26 |
| Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer Docetaxel, Epirubicin, Oxaliplatin - Locally Advanced Unresectable Gastric Cancer, Metastatic Gastric Cancer | Phase 3 | Terminated | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | 171 | 2013-01-01 | 2019-10-09 |
| XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC) XELOX, FOLFOX - Gastric Carcinoma Stage IV | Phase 3 | Terminated | Dong-A University Hospital | 42 | 2012-12-01 | 2014-11-04 |
| First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma Rilotumumab, Placebo, Epirubicin - Gastric Cancer | Phase 3 | Terminated | Amgen | 609 | 2012-10-01 | 2016-02-09 |
| A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Taxane, trastuzumab emtansine - Gastric Cancer | Phase 2 / Phase 3 | Terminated | Hoffmann-La Roche | 415 | 2012-09-03 | 2017-05-12 |
| Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer positive cytology with HIPEC - Gastric Cancer, Peritoneal Carcinomatosis | Phase 2 / Phase 3 | Terminated | University Hospital Tuebingen | 3 | 2012-09-01 | 2018-01-30 |
| Laparoscopy-assisted Proximal Gastrectomy Versus and Laparoscopy-assisted Total Gastrectomy Laparoscopy-assisted gastrectomy - Gastric Cancer | Phase 3 | Terminated | Seoul National University Bundang Hospital | 7 | 2012-07-01 | 2017-01-09 |
Showing 20 of 32. Sign in to see all of them.
Stomach Neoplasms (21) · Gastroparesis (5) · Diabetes Mellitus (4) · Colonic Neoplasms (2) · Duodenal Ulcer (2) · Esophageal Neoplasms (2) · Esophagitis, Peptic (2) · Gallbladder Neoplasms (2) · Liver Neoplasms (2) · Lung Neoplasms (2) · Pancreatic Neoplasms (2) · Peptic Ulcer (2) · Stomach Ulcer (2) · Vomiting (2) · Acute Coronary Syndrome (1)
Digestive System Diseases (31) · Gastrointestinal Diseases (31) · Digestive System Neoplasms (21) · Neoplasms (21) · Neoplasms by Site (21) · Gastrointestinal Neoplasms (20) · Pathological Conditions, Signs and Symptoms (9) · Intestinal Diseases (7) · Signs and Symptoms (7) · Endocrine System Diseases (6) · Duodenal Diseases (5) · Neurologic Manifestations (5) · Paralysis (5) · Esophageal Diseases (4)
Cisplatin (6) · Capecitabine (5) · relamorelin (5) · Fluorouracil (3) · S 1 (combination) (3) · Epirubicin (2) · Lansoprazole (2) · Oxaliplatin (2) · Proton Pump Inhibitors (2) · rilotumumab (2) · Ado-Trastuzumab Emtansine (1) · Arthotec (1) · Arthrotec (1) · Aspirin (1) · Clopidogrel (1)
Allergan (5) · Amgen (3) · Hoffmann-La Roche (2) · AstraZeneca (1) · Auron Healthcare GmbH (1) · Bristol-Myers Squibb (1) · Cogentus Pharmaceuticals (1) · Daewoong Pharmaceutical Co. LTD. (1) · Dong-A University Hospital (1) · Eastern Network of Cancer Immunological Therapy, Japan (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente (1) · Japan Clinical Oncology Group (1) · Kuhnil Pharmaceutical Co., Ltd. (1) · Massachusetts General Hospital (1)
South Korea (15) · United States (14) · Germany (13) · Poland (11) · Brazil (10) · Hungary (10) · Belgium (9) · Italy (9) · Mexico (9) · Spain (9) · Ukraine (9) · United Kingdom (9) · Australia (8) · Bulgaria (8) · Canada (8)
Harvy Schneier (2) · Alessandro Bertolini, MD (1) · Andrea Ciarlo, MD (1) · Christoph Schuhmacher (1) · Claudio Graiff, MD (1) · Claudio Verusio, MD (1) · Daris Ferrari, MD (1) · Domenico Amoroso, MD (1) · Domenico Bilancia, MD (1) · Domenico Cristiano Corsi, MD (1)
PMID 16887481, PMID 20925534, PMID 21060024, PMID 21104822, PMID 25605628, PMID 25712685, PMID 27012778, PMID 28343975, PMID 28536493, PMID 28680717, PMID 28911091, PMID 28958504, PMID 30706247, PMID 34878659, PMID 38308771, PMID 40148033, PMID 40341124
2017 (3), 2019 (1), 2023 (1), K23CA115908 (1)